Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Eur J Cancer. 2013 Jun 18;49(14):3020–3028. doi: 10.1016/j.ejca.2013.05.013

Figure 4. PLK1 abrogation inhibits GBM tumor growth in-vivo.

Figure 4

(A) U251 cells were implanted subcutaneously into nude mice and tumor growth was monitored over time. Tumors grown to ≈172 mm3 were randomized to one of four treatment arms: vehicle treated control, GSK461364A (25 mg/kg), GSK461364A (50 mg/kg), or GSK461364A (100 mg/kg). Mice were treated with two doses of GSK461364A or DMSO control four days apart. Tumor volume plotted as the mean volume ± SD. (B) Cell lysates from control and GSK461364A treated tumors were measured for PLK1 protein levels by Western blot analysis using actin as a loading control. PLK1/actin ratio is shown.